Core Scientific (CORZ) Could Be 61% Undervalued On Its HPC Expansion Narrative

Core Scientific stock moves without a clear headline catalyst

Core Scientific (CORZ) has been under pressure recently, with the share price down 0.8% over the past day and 2.8% over the past week, even without a clear single news event driving the move.

The slide has extended over longer stretches, with the stock down 28% over the past month and 42% over the past 3 months, keeping Core Scientific firmly on the radar of investors tracking sentiment in bitcoin mining and AI-focused infrastructure plays.

That recent slump extends a weaker run, with Core Scientific’s year to date share price return down 18.1% and 1 year total shareholder return down 32.3%. This signals fading momentum as investors reassess both bitcoin exposure and AI infrastructure risk around the stock.

Scan beyond Core Scientific and see how other AI infrastructure and bitcoin related miners are trading right now with our hand picked list of 55 AI infrastructure stocks.

Core Scientific trades at US$13.10 while the average analyst target sits near US$32.62, a wide gap after a steep pullback. How far does fair value really sit from today’s price?

Most Popular Narrative: 61% Undervalued

Against the last close at $13.10, the most followed narrative pins Core Scientific’s fair value near $33.90. This represents a wide gap that rests on aggressive growth and margin assumptions over the next few years.

The company is expanding HPC infrastructure capacity by reallocating resources from Bitcoin mining, adding new sites, and extending existing ones, expecting to drive future revenue growth as data center needs rise. Core Scientific’s ability to diversify its customer base and reduce reliance on CoreWeave as a primary client could improve margins and provide more stable revenue streams in the long term.

See why 64 investors see Core Scientific as 61% undervalued.

Result: Fair Value of $33.90 (UNDERVALUED)

Still, the narrative around Core Scientific could shift quickly if execution on the CoreWeave and AMD capacity buildout slips, or if client concentration risk starts to bite.

Find out about the key risks to this Core Scientific narrative.

Another View: Core Scientific Looks Expensive On Sales

The narrative around Core Scientific leans heavily on future earnings, yet the current P/S ratio of 9.6x tells a tougher story. That is far above the US Software industry on 4x and above the fair ratio of 5.4x that the market could move toward. This suggests a lot of optimism is already in the price and leaves less room if expectations cool.

For investors cross checking these signals, the numbers raise a simple question. Is this a case of paying up early for a potential turnaround, or is it better to wait until the valuation gets closer to that fair ratio?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Plenty of opinions are already priced into Core Scientific, but your decision should rest on your own view of the risk and reward trade off. Start by weighing the 1 key reward and 3 important warning signs.

Looking for more Core Scientific investment ideas?

If Core Scientific no longer feels like the only place to focus, you may want to broaden your watchlist with a few targeted sets of stocks that match different investing goals.

• Hunt for potential mispriced opportunities by scanning a hand picked pool of 27 high quality undervalued stocks with strong fundamentals already on display.
• Build a steadier income stream by reviewing companies in the 5 dividend fortresses that combine higher yields with disciplined payout histories.
• Sleep easier at night by filtering for 30 resilient stocks with low risk scores that pair resilient balance sheets with lower overall risk scores.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com